Application of ADC in First-Line Treatment of NSCLC and Interpretation of Results from the EVOKE-02 Study

Application of ADC in First-Line Treatment of NSCLC and Interpretation of Results from the EVOKE-02 Study

2024.02.13
The 24th World Conference on Lung Cancer (WCLC) was held from September 9 to 12, 2023, in Singapore, organized by the International Association for the Study of Lung Cancer (IASLC). During the oral presentation session on September 10, the EVOKE-02 study, exploring the first-line treatment of advanced non-small cell lung cancer (NSCLC) with the combination of sacituzumab govitecan (SG) and pembrolizumab, revealed its preliminary results. The study demonstrated an objective response rate (ORR) of 56% and a disease control rate (DCR) of 82% for stage IV NSCLC patients, laying the foundation for a new treatment strategy. " Oncology Frontier" invited Dr. Stephen V. Liu from Georgetown University Lombardi Comprehensive Cancer Center and Dr. Shun Lu from Shanghai Chest Hospital and Shanghai Jiao Tong University for a virtual dialogue to discuss the significance of the EVOKE-02 study and the future possibilities in NSCLC treatment.
Dr. Myron Schwartz: The Development and Prospects of Multidisciplinary Comprehensive Treatment of Liver Cancer

Dr. Myron Schwartz: The Development and Prospects of Multidisciplinary Comprehensive Treatment of Liver Cancer

2024.02.01
Primary liver cancer is one of the common malignant tumors worldwide. With the development of modern biomedical technology, clinical surgical techniques, and minimally invasive treatment techniques, the surgical treatment level of liver cancer has made significant progress. At the recently concluded global academic event in the field of liver cancer - the 17th Annual Meeting of the International Liver Cancer Association (ILCA), Dr. Myron Schwartz of Mount Sinai Hospital, the U.S., delivered a keynote report on the progress made in liver cancer surgical treatment in recent years. Hepatology Digest specially invited Dr. Schwartz for an in-depth interview on the evolution of future liver cancer clinical treatment strategies and the opportunities and challenges that liver cancer surgery will face.
Dr. Masatoshi Kudo: “T+A” Shows Significant Clinical Benefits in Intermediate-Stage HCC Patients Unsuitable for TACE Treatment

Dr. Masatoshi Kudo: “T+A” Shows Significant Clinical Benefits in Intermediate-Stage HCC Patients Unsuitable for TACE Treatment

2024.02.01
 Hepatocellular carcinoma (HCC) is a prevalent malignant tumor posing a significant threat to human health with considerable heterogeneity. Specifically, intermediate-stage HCC spans a range from liver function reserve ChHepatology Digest-Pugh A grade (5 points) to B grade (9 points), tumor sizes from 5 cm to >10 cm, and the number of nodules from 4 to >10. There is an urgent need for refined clinical treatments. Significant advancements in systemic treatments have recently improved the survival of advanced-stage HCC patients. Systemic treatments for intermediate-stage HCC have become a major focal point in the field. At the recently concluded 17th International Liver Cancer Association (ILCA) Annual Meeting, Dr. Masatoshi Kudo from Kindai University, Japan, presented an oral report on a clinical study (REPLACEMENT study, Abstract No. O-15) of atezolizumab combined with bevacizumab (referred to as “T+A”) for patients with intermediate-stage HCC unsuitable for TACE treatment. We had the privilege to interview Dr. Kudo for insights into this research and its findings.